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1. Introduction 
Have we succumbed to a new tyranny in medicine—evidence-based medicine? With 
apologies to my former professor, Dr. David Sackett! but has the randomized controlled trial 
(RCT) become a new idol? Indeed, EBM has been satirized as a new religion.1 At the risk of 
not being ‘politically correct”,2 I would argue that evidence-based medicine (EBM) can be 
abused and substituted for sound clinical judgment. The exponents of the new paradigm we 
call evidence-based medicine recognized this: “Thus, knowing the tools of evidence-based 
practice is necessary but not sufficient for delivering the highest quality of patient care. In 
addition to clinical expertise, the clinician requires compassion, sensitive listening skills, and 
broad perspectives from the humanities and social sciences.”3 Evidence-based medicine, 
when properly understood and applied, improves patient outcomes but it is often 
misunderstood and used inappropriately.4 It is important to recognize the limitations of 
EBM as well as its benefits in the care of our patients. Strauss and McAlister point out some 
of the limitations of EBM5: “ shortage of coherent, consistent scientific evidence, difficulties 
in applying evidence to the care of individual patients, barriers to the practice of high-
quality medicine, limited time and resources, paucity of evidence that evidence-based 
medicine works.” One common example that many community generalists would share 
around the concept of ‘barriers to the practice of high-quality medicine’ is the issue of a lack 
of resources for the appropriate care of one’s patient. For example, there is an unacceptable 
waiting time for a child you suspect of having autism to see a child psychiatrist to confirm 
the diagnosis and enable the family to obtain publicly funded resources for early 
intervention. This is equally true for other psychiatric disorders. Indeed, the wait time for 
many subspecialties in pediatrics is often in the order of many months.  
Evidence-based medicine is an offshoot of the philosophical movement known as scientific 
positivism. Scientific positivism is a particular philosophy, which states that only that which 
is scientifically verifiable is true. The critique of scientific positivism is that its central 
premise is itself not scientifically verifiable but must be accepted as a sort of first principle or 
axiom. Similarly, the principle of evidence-based medicine must be itself accepted as an 
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axiom of the system. This can be seen if we frame the following question, ‘what is the 
evidence that evidence-based medicine improves patient outcomes?’ In fact, there is no such 
evidence since such a trial would be extremely difficult and unethical to do. “Evidence-
based medicine, like other models of care, has limitations …efforts need to be directed 
toward … conducting studies to test whether and how evidence-based medicine affects 
processes of care and patient outcomes.”6  
Let me clearly state that my comments are not to be taken as an excuse to return to magical 
thinking or charlatanism. The outstanding achievements of modern medicine have been 
accomplished through the rigorous application of the scientific method in developing 
evidence-based guidelines. Patient outcomes have certainly improved with the application 
of these treatments. We are also aware of therapeutic disasters when the principles of 
controlled observations and rigorous research designs are not observed. (eg tying off the 
internal mammary arteries in the treatment for angina pectoris7).  
Having said this, there is an a priori reason why we should not substitute evidence-based 
medicine for a more holistic approach and that is quite simply that the evidence is never 
complete. This is a fundamental feature of the scientific method and it is applicable in all the 
sciences. Recently, for example, the most fundamental aspect of Einstein’s theory of special 
relativity, the fixed speed of light (299,792,458 m/sec) has been challenged by experiments 
at OPERA which demonstrated that neutrinos travel slightly faster than the speed of light.8 
If this finding is duplicated by other laboratories, then our understanding of the 
fundamental features of space-time will need to be revised. Until this announcement, it was 
unthinkable that Einstein’s constant was not true since his theory of special relativity made 
many predictions subsequently validated by observation. However, this latest challenge to 
Einstein should not surprise us because the basic hermeneutic underlying the scientific 
method depends on theories validated by observations; as the observations change through 
more and more sophisticated technological advances, the theories need to be modified. 
Physicists have yet to achieve the unifying theory which combines Einstein’s theory of 
special relativity and quantum mechanics which at present are incompatible. Evidence-
based medicine is based on the scientific method and it is subject to the same caveats as 
physics and cosmology. Theoretically, the evidence base will continue to unfold ad infinitum 
since there is no principle which enables us to know that the end of the evidence has been 
reached and there can be no further evidence. We can only act in the concrete world of sick 
patients with the evidence at hand, as best as it, knowing that perhaps further evidence will 
prove us wrong. 
A recent discussion in the New England Journal of Medicine highlights this problem and 
introduces a new dynamic.9 The authors relate the case of a 13 year-old girl with lupus 
erythematosus with nephritic syndrome, antiphospholipid antibodies and pancreatitis. They 
site the difficulty of knowing whether or not to anticoagulate this patient since there is no 
data in the pediatric literature on this question. There would also be the danger of inducing 
bleeding. A survey of other pediatric rheumatologists did not produce a consensus. Since 
there were no RCT’s on this question, the authors state that they turned to their hospital’s 
EMR database and within the space of a few hours obtained their experience over the 
previous five years to arrive at an ‘electronic cohort’. Through this retrospective analysis 
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they opted to treat their patient with anticoagulants. This was not a RCT of anticoagulants 
versus no anticoagulants in a selected group of patients with SLE but physicians using their 
judgment based on past experience. “Did we make the correct decision for our patient? 
Thrombosis did not develop, and the patient did not have any sequelae related to her 
anticoagulation; truthfully, though, we may never really know. We will, however, know 
that we made the decision on the basis of the best data available—acting…in the light of 
experience guided by intelligence.”10  
There is always the possibility of newer evidence that will invalidate a particular diagnosis, 
therapeutic choice or diagnostic test. Newer diagnostic tools inevitably result in a greater 
understanding of pathophysiology, e.g. the explosion of molecular genetics. Often, there is 
no definitive RCT in the literature to help one with a clinical decision. Sometimes the results 
of a Cochrane summary, i.e the evaluation of available RCT’s regarding a particular 
question, are contradictory or inconclusive.11 One could also argue that the ‘gold standard’ 
RCT is best used when a clearly defined therapy is being tested i.e. drug A vs drug B in a 
well-defined group of patients. This may be the case in a secondary or tertiary care center 
but is not the case in primary care where multiple pathologies may be at work in a broader 
group of patients. An RCT may not be the most useful tool when evaluating problems in 
primary care where there is a less highly selected group of patients with a single defined 
etiology. 12 The outcome measure used in an RCT may be inappropriate as in the case of 
rosiglitazone where the primary outcome measure was the lowering of glycated 
hemoglobin. The clinical trials leading up to the release of this drug on the markets focused 
on an outcome that may not be relevant (glycemic control ) and ignored important side 
effects, assuming that a reduction in glycated hemoglobin translates into improved patient 
outcome. Indeed the side effects (weight gain, edema, and changes in lipids) detected 
during the clinical trials may well be more important with regard to outcome than glycemic 
control. Nissen and Wolski in fact showed that rosiglitazone increases the risks of 
myocardial infarction, despite improved glycemic control. 13  
Recently, Ioannidis has argued cogently that much published research is eventually shown 
to be false. This results from the attempts to achieve a conclusive result based on a single 
study assessed statistically using a p value of <.05. “A finding from a well-conducted, 
adequately powered randomized controlled trial starting with a 50% pre-study chance that 
the intervention is effective is eventually true about 85% of the time. …Conversely, a meta-
analytic finding from inconclusive studies where pooling is used to “correct” the low power 
of single studies, is probably false if R<1:3. Research findings from underpowered, early-
phase clinical trials would be true about one in four times, or even less frequently if bias is 
present.”14 There is also a darker side to the quest for evidence-based guidelines when vital 
evidence is withheld from the public domain, or falsified, invalidating the ‘evidence’ upon 
which a particular therapy is recommended. An example of this occurred with the clinical 
trials of a new iron-chelator, deferiprone. Apotex, the pharmaceutical firm developing the 
new drug, would not allow the publication of negative data. While researching a new iron-
chelating agent, deferiprone, for Apotex, Nancy Olivieri of the Hospital for Sick Children in 
Toronto, uncovered data indicating that the drug would not provide long-term control of 
iron overload in patients with thalassemia major and worsened hepatic fibrosis. The 
pharmaceutical firm funding her research, Apotex, would not allow her to publish the data 
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because of a research contract. Dr. Olivieri published the data regardless 15and a major 
controversy regarding academic freedom ensued at great personal cost to Dr. Olivieri.16 
Another example is that of the COX-2 inhibitors. In the enthusiasm to release a new drug, 
rofecoxib, a COX-2 inhibitor, Bombardier et al17 overlooked an important cardiovascular 
side effect in a subgroup of patients even though the drug showed promise in the group of 
patients for which the clinical trial was designed, those with rheumatoid arthritis. 
Subsequent analysis of the data indicating a substantial risk for cardiovascular events in 
patients taking the drug, resulted in the withdrawal of rofecoxib(Vioxx) from the market. . 
This has recently led to the institution of a registry for all RCT’s; any researcher who wishes 
to publish in any of the major medical journals will now have to insure that their RCT is 
registered in the public domain, with all data both positive and negative available.18  
There is also the moral issue of using data from trials conducted unethically as in the 
infamous Tuskegee Syphilis study in which 399 poor black sharecroppers were denied 
effective treatment so that researchers could follow the natural history of syphilis.19Similar 
comments can be made about the Nazi doctors and the use of eponyms such as 
Hallervorden-Spatz syndrome, honouring a pathologist, Hallervorden, who actively 
participated in the Nazi euthanasia program in order to obtain specimens of human brains 
for his research.20  
Evidence can be published in recognized medical journals that is false because it has been 
unethically manipulated to justify a particular conclusion. Such was the case of the 
unjustified link between MMR immunization and autism published in The Lancet by Dr. 
Andrew Wakefield.21 This publication was not only wrong but the data was manipulated as 
was shown by Brian Deer’s exposé published in the British Medical Journal in 2011.22 
Wakefield postulated that 12 children had a ‘new syndrome’ of enterocolitis and regressive 
autism. In fact, 3/12 patients did not have regressive autism. 5/12 had a previous diagnosis 
of developmental problems long before receiving MMR vaccine and the symptoms of 
autism occurred months after the MMR was given and not within days. The study was 
further biased by the fact that the patients were recruited by known anti-MMR campaigners. 
Furthermore Dr. Wakefield stood to make financial gain through litigation by suing the 
pharmaceutical firms manufacturing the vaccine if his ‘research’ was generally accepted. 
The Lancet subsequently retracted the article in 2010 after untold damage had been done.23 
The false link between MMR and autism has caused needless worry to parents and along 
with other factors has led to a decline in herd immunity to measles with resultant increase in 
the number of cases in the developed world, where previously measles had almost been 
eliminated. As of October 2011, 26,074 cases of measles have been reported in European 
member states, with 14,000 cases in France alone. This has resulted in 7288 hospitalizations 
and 9 deaths.24 Thus, while evidence-based practice is desirable, it is not always possible 
because of contamination of the evidence by either incomplete or changing evidence, and 
unethical manipulation of evidence. Because of these failures, evidence-based medicine 
cannot always lead to the healing and relief from suffering that our patients seek. 
Paradoxically, they turn to complementary and alternative medicine (CAM) which often has 
less of an evidence base than traditional medicine. 
A further issue is that conclusions drawn from RCT’s are based on a statistical assessment of 
the participants in the clinical trial but you must apply the conclusion to your particular 
www.intechopen.com
 
Evidence-Based Medicine – Perspectives of a Community-Based Pediatrician 
 
143 
patient. The danger is that your particular patient may not be similar to the patients in the 
clinical trial. This is especially a problem when trying to apply the results of a study, which 
has been done in a secondary or tertiary care center. The patients enrolled in such a trial 
may be quite different than the patients seen in a community practice. At any given clinical 
encounter, the physician does not have all the information needed to make an evidence-
based decision. For example, every individual patient has a particular pharmacogenetic 
profile, which is largely unknown. Another major problem in pediatrics is, of course, that 
most drugs are ‘orphans’ i.e. there is no good information derived from studies in pediatrics 
and so we ‘extrapolate’ from adult studies. It is good to remind oneself that ‘extrapolation’ 
means that we are outside the principle of evidence-based medicine—we are extrapolating 
or going beyond the evidence on an assumption. The assumption is that what holds true for 
adult patients will hold true for pediatric patients. Of course, the ‘assumption’ is not 
evidence-based! Moreover, we now know that this assumption is often untrue. 
Consequently, evidence-based principles sometimes ‘break down’ in the concrete world in 
which individual physicians must act.  
The renowned mediaeval philosopher/theologian Thomas Aquinas made a distinction, 
derived from Aristotle, between the speculative and practical intellect. The speculative 
intellect is the locus of analytical, theoretical thinking and this is the home of evidence-based 
medicine. The practical intellect, however, is the locus of applying evidence-based medicine 
to the practice of medicine: the specific judgment (having taken into account the evidence 
and the particulars of this patient before me) that the physician makes in determining the 
appropriateness of a particular treatment. The practical intellect is the final common 
pathway leading to a particular judgment for a particular patient. Let us take an example. A 
9 year old girl is brought to your office at 5:00 PM on a Friday afternoon complaining of an 
earache. You correctly diagnose an otitis media. Evidence-based medicine would suggest 
that the correct course is not to prescribe an antibiotic but rather to prescribe analgesics and 
re-examine the patient 48 hours later; if no resolution, then it is appropriate to prescribe an 
antibiotic. But other considerations may override the principles of evidence-based medicine: 
the mother may not be able to come back for a re-examination or the family is about to catch 
a plane for a holiday etc. Thus, a more holistic approach is mandated and the principle of 
evidence-based medicine breaks down. There is always a certain unpredictability in our 
encounters with patients. 
Let us take another example. There are many excellent pediatric hospitals that care for 
patients with cystic fibrosis. A recent article in The New Yorker describes how all of them 
follow the same evidence-based guidelines for the treatment of cystic fibrosis and yet if one 
examines their results, they are distributed along a bell curve; most of the hospitals were 
only average in their results and one hospital stood out: the Babies and Children’s Hospital 
in Cleveland where a respirologist named LeRoy Matthews had established a program for 
the treatment of cystic fibrosis in 1957. When national mortality rates for cystic fibrosis in 
the best centers was around 20%, Matthews claimed that his mortality rate was less than 2%. 
What was the difference? The difference turned out to be innovation and constantly 
challenging the evidence-based guidelines which record past experience.25 We must remain 
focused on our patients and challenge ourselves to do better, to go beyond the evidence-
based guidelines in order to excel, thereby constantly improving the guidelines themselves.  
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A recent essay in the New England Journal of Medicine entitled, The New Language of 
Medicine argues that we are in danger of losing the notion that physicians are healers. We 
now refer to ourselves as ‘providers’ who have a ‘product’ to sell and our patients are now 
‘consumers’ buying this product. “Beyond introducing new words, the movement toward 
industrializing and standardizing all of medicine (rather than just safety and emergency 
protocols) has caused certain terms that were critical to our medical education to all but 
disappear. ‘Clinical judgment’, for instance, is a phrase that has fallen into disgrace, replaced 
by ‘evidence-based practice’, the practice of medicine based on scientific data. But evidence 
is not new; throughout our medical education beginning more than three decades ago, we 
regularly examined the scientific evidence for our clinical practices. On rounds or in clinical 
conferences, doctors debated the design and results of numerous research studies. But the 
exercise of clinical judgment, which permitted assessment of those data and the application 
of study results to an individual patient, was seen as the acme of professional practice.”26 
In conclusion, there have always been two streams in medicine: the Hippocratic and 
Aesculapian. Evidence-based medicine and guidelines belong to the Hippocratic stream. 
The Aesculapian stream emphasizes healing and the importance of the psychological and 
spiritual aspects involved in healing. Because physicians do not always take this into 
account, many patients turn to complementary medicine for relief of their symptoms. 
Modern 21st Century medicine needs to be reminded of both the Hippocratic and the 
Aesculapian heritage in its long and renowned history. A good physician must take a 
holistic approach in any clinical encounter with a suffering human being. Evidence-based 
medicine must never be abandoned but it must be incorporated into the practical intellect along 
with the particular concrete aspects of this patient in order to make an appropriate and 
efficacious therapeutic decision. The cornerstones of caring for our patients and practicing 
good medicine are the encounter with the patient through our history and physical 
examination. We then combine this with the principles of evidence-based medicine, 
recognizing its hermeneutic weakness, to arrive at the best possible outcome for our patient. 
It is then that evidence-based medicine becomes “’ebullience-based medicine,’ a lively, 
enthusiastic, continually joyful expression of our good fortune at having the privilege to be 
able to care for and advocate for children.”27 
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